Comment on CMS-2026-1255-0001

Summary: Myriad Genetics, a molecular diagnostic laboratory, supports CMS's efforts to reduce burdensome prior authorization practices by Medicare Advantage (MA) organizations. They specifically advocate for a rule prohibiting MA organizations from requiring prior authorization for services covered under National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs).